Edition:
United States

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

75.97USD
20 Jul 2018
Change (% chg)

$0.14 (+0.18%)
Prev Close
$75.83
Open
$75.54
Day's High
$76.19
Day's Low
$75.18
Volume
207,985
Avg. Vol
314,854
52-wk High
$95.82
52-wk Low
$63.69

Select another date:

Wed, May 16 2018

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra Cream, 1%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF SOOLANTRA® CREAM, 1% Source text for Eikon: Further company coverage:

Select another date: